ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 057,80
-0,92%
Dow Jones
38 852,86
-0,55%
DAX
18 677,87
-0,45%
Brent Oil
84,315
1,77%
Bitcoin
68 071,23
-1,91%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Rezolute Inc (RZLT)

  7. Rezolute Inc (RZLT) Actualités

RZLT

Rezolute (RZLT)

Rezolute Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RZLT
DateHeureSourceTitreSymboleSociété
28/05/202420h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RZLTRezolute Inc
24/05/202420h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RZLTRezolute Inc
21/05/202422h05GlobeNewswire Inc.Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)NASDAQ:RZLTRezolute Inc
15/05/202422h25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RZLTRezolute Inc
15/05/202422h05GlobeNewswire Inc.Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateNASDAQ:RZLTRezolute Inc
23/04/202414h00GlobeNewswire Inc.Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingNASDAQ:RZLTRezolute Inc
06/03/202413h30GlobeNewswire Inc.Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)NASDAQ:RZLTRezolute Inc
13/02/202423h00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RZLTRezolute Inc
13/02/202422h05GlobeNewswire Inc.Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business UpdateNASDAQ:RZLTRezolute Inc
24/01/202414h00GlobeNewswire Inc.Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerNASDAQ:RZLTRezolute Inc
23/01/202414h00GlobeNewswire Inc.Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital HyperinsulinismNASDAQ:RZLTRezolute Inc
14/12/202314h00GlobeNewswire Inc.Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital HyperinsulinismNASDAQ:RZLTRezolute Inc
13/12/202314h00GlobeNewswire Inc.Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)NASDAQ:RZLTRezolute Inc
30/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RZLTRezolute Inc
22/11/202323h16Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:RZLTRezolute Inc
17/11/202314h00GlobeNewswire Inc.Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology DayNASDAQ:RZLTRezolute Inc
15/11/202315h08Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:RZLTRezolute Inc
13/11/202322h05GlobeNewswire Inc.Rezolute Reports First Quarter Fiscal 2024 ResultsNASDAQ:RZLTRezolute Inc
17/10/202314h00GlobeNewswire Inc.Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital HyperinsulinismNASDAQ:RZLTRezolute Inc
13/10/202322h30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RZLTRezolute Inc
11/10/202314h00GlobeNewswire Inc.Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated HyperinsulinismNASDAQ:RZLTRezolute Inc
14/09/202322h22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RZLTRezolute Inc
14/09/202322h05GlobeNewswire Inc.Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company ProgressNASDAQ:RZLTRezolute Inc
06/09/202313h00GlobeNewswire Inc.Rezolute to Participate in Upcoming Investor Conferences in SeptemberNASDAQ:RZLTRezolute Inc
27/06/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RZLTRezolute Inc
27/06/202322h05GlobeNewswire Inc.Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital HyperinsulinismNASDAQ:RZLTRezolute Inc
11/05/202322h25Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RZLTRezolute Inc
11/05/202322h05GlobeNewswire Inc.Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company ProgressNASDAQ:RZLTRezolute Inc
03/05/202314h56Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:RZLTRezolute Inc
12/04/202322h20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:RZLTRezolute Inc
 Showing the most relevant articles for your search:NASDAQ:RZLT

Dernières Valeurs Consultées

KOSDAQ
060230
Sonid
AMEX
JIB
Janus Henderson Sustaina...
HITB
STNDBTC
Standard
TG
ELEC
HANetf ICAV
ASX
PPCHB
Peet
LSE
BRND
Wt B.crud P.rol
NYSE
GLOG
GasLog
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés